Here’s a Heartwarming Story of Innovation in the Pharmaceutical Business

Facts matter: Sign up for the free Mother Jones Daily newsletter. Support our nonprofit reporting. Subscribe to our print magazine.


Apparently the new hotness in the pharmaceutical industry is this: (1) Find an old, generic drug that’s used only rarely and made by only one company. (2) Buy it. (3) Jack up the price astronomically. Since you have a monopoly, there’s not much that anyone can do about it. And since it’s a rarely used drug, it’s not really worth anyone’s time to manufacture a competing version.

At the New York Times, Andrew Pollack spotlights this problem with the story of Daraprim, which was acquired last month by an ex-hedge fund manager who immediately raised the price from $13.50 per tablet to $750 per tablet. He offered up two excuses for doing this:

Daraprim, known generically as pyrimethamine, is used mainly to treat toxoplasmosis, a parasite infection that can cause serious or even life-threatening problems for babies born to women who become infected during pregnancy, and also for people with compromised immune systems, like AIDS patients and certain cancer patients.

Martin Shkreli, the founder and chief executive of Turing, said that the drug is so rarely used that the impact on the health system would be minuscule and that Turing would use the money it earns to develop better treatments for toxoplasmosis, with fewer side effects.

“This isn’t the greedy drug company trying to gouge patients, it is us trying to stay in business,” Mr. Shkreli said. He said that many patients use the drug for far less than a year and that the price was now more in line with those of other drugs for rare diseases.

“This is still one of the smallest pharmaceutical products in the world,” he said. “It really doesn’t make sense to get any criticism for this.”

….Turing’s price increase could bring sales to tens or even hundreds of millions of dollars a year if use remains constant.

So there you have it. It’s such a tiny market that, really, who cares? Chill, people. And anyway, they’re going to use their newly found profits to develop wonderful new treatments for toxoplasmosis. I wouldn’t hold my breath for that to happen. Besides, doctors who use the drug say that Daraprim works fine and no one’s really clamoring for something better.

Welcome to the 21st century pharmaceutical biz, working hard to find new and innovative ways of gouging the most vulnerable members of society. And for once, we can truly say that this could happen only in America, since no other country would allow it. Makes you proud, doesn’t it?

WE'RE TAKING A SHORT BREAK…

from the big banner at the top of our pages asking for the donations that make Mother Jones' nonprofit journalism possible. But we still have upwards of $300,000 to raise by June 30, whether we get there is going to come down to the wire, and we can't afford to come up short.

If you value the reporting you get from Mother Jones and you can right now, please join your fellow readers who pitch in from time to time to keep our democracy-advancing, justice-seeking journalism charging hard (and to help us avoid a real budget crunch as June 30 approaches and our fiscal year ends).

payment methods

WE'RE TAKING A SHORT BREAK…

from the big banner at the top of our pages asking for the donations that make Mother Jones' nonprofit journalism possible. But we still have upwards of $300,000 to raise by June 30, whether we get there is going to come down to the wire, and we can't afford to come up short.

If you value the reporting you get from Mother Jones and you can right now, please join your fellow readers who pitch in from time to time to keep our democracy-advancing, justice-seeking journalism charging hard (and to help us avoid a real budget crunch as June 30 approaches and our fiscal year ends).

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate